血清p-tau181与帕金森病的相关性  

Correlation between serum p-tau181 and Parkinson’s disease

作　　者：田章林 龙波 董语涵 魏有东[1,2] TIAN Zhanglin;LONG Bo;DONG Yuhan;WEI Youdong(The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China;Chongqing Key Laboratory of Neurobiology,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院,重庆400016 [2]重庆神经生物学重点实验室,重庆400016

出　　处：《中国实用神经疾病杂志》2024年第2期139-143,共5页Chinese Journal of Practical Nervous Diseases

基　　金：重庆市卫生计生委医学科研计划面上项目(编号:2017MSXM023)。

摘　　要：目的探究帕金森病(PD)患者血清磷酸化tau181(p-tau181)浓度及其与疾病严重程度、认知损害、患者功能预后的相关性。方法纳入2021-07—2022-02于重庆医科大学附属第一医院神经内科住院或门诊就诊的PD患者40例和同期健康对照(HC)35例为研究对象。采用酶联免疫吸附试验(ELISA)检测血清p-tau181水平。入院或就诊时评估帕金森病统一评分量表(UPDRS)和Hoehn-Yahr(H-Y)分期量表,以评估PD患者的疾病严重程度。认知功能由蒙特利尔认知评估(MoCA)量表测评。6个月后随访患者UPDRS评分及H-Y分期,进一步评估血清p-tau181与患者预后的相关性。结果与HC相比,PD患者血清p-tau181水平升高,但差异无统计学意义[1.01(0.28~2.63)ng/L比0.53(0.04~3.72)ng/L,P=0.55]。PD早期和晚期患者p-tau181水平差异无统计学意义(P=0.80),认知损害PD患者、认知正常PD患者与HC者p-tau181水平差异无统计学意义(P=0.63)。p-tau181与病程(r=-0.14,P=0.37)、UPDRS评分(r=0.02,P=0.89)、MoCA评分(r=0.16,P=0.32)均无相关性。预后良好组与预后不佳组血清p-tau181水平表达无统计学差异(P=0.74)。结论p-tau181在帕金森病患者血清表达增加,与疾病严重程度、认知损害、功能预后无明确相关性。Objective To investigate the correlation between serum phosphorylated tau 181(p-tau181)concentration and disease severity,cognitive impairment and functional prognosis in patients with Parkinson’s disease(PD).Methods We recruited consecutive PD patients and healthy controls(HC)in the First Affiliated Hospital of Chongqing Medical University from July 2021 to February 2022.Serum p-tau181 levels were detected by the p-tau181 enzyme-linked immunosorbent assay(ELISA).The unified Parkinson’s disease rating scale(UPDRS)and the Hoehn and Yahr staging scale(H-Y)were assessed on admission to evaluate the disease severity in patients with PD.Cognitive status was measured by the Montreal cognitive assessment(MoCA).The UPDRS score and H-Y stage were followed up 6 months later to further evaluate the correlation between serum p-tau181 and prognosis.Results We finally recruited 75 patients,including 40 PD patients and 35 HC.Serum p-tau181 levels were not significantly increased in PD patients compared with HC(1.01(0.28-2.63)ng/L vs 0.53(0.04-3.72)ng/L,P=0.55).Besides,there was no significant difference in p-tau181 levels between patients at early and advanced stage of PD(P=0.80),as well as between cognitively impaired PD patients,PD patients with normal cognition,and HC(P=0.63).Moreover,p-tau181 had no correlation with disease duration(r=-0.14,P=0.37),UPDRS score(r=0.02,P=0.89),and MoCA score(r=0.16,P=0.32).There was no significant difference in serum p-tauu181 expression between good prognosis group and poor prognosis group(P=0.74).Conclusion The expression of serum p-tau181 in PD patients increases,and there is no clear correlation with disease severity,cognitive impairment or functional prognosis.

关 键 词：帕金森病 磷酸化tau蛋白181 认知损害 疾病严重程度 功能预后 

分 类 号：R742.5[医药卫生—神经病学与精神病学]